earnings
confidence high
sentiment positive
materiality 0.80
Merck Q4 2021 revenue $13.5B (+24%), Non-GAAP EPS $1.80; FY2022 guidance issued
Merck & Co., Inc.
2021-FY EPS reported
$5.14
revenue$48,704,000,000
- Q4 2021 sales $13.5B (+24% YoY); GAAP EPS $1.51, Non-GAAP EPS $1.80 (vs $0.98).
- Full-year 2021 sales $48.7B (+17%); GAAP EPS $4.86, Non-GAAP EPS $6.02.
- KEYTRUDA FY sales $17.2B (+20%); GARDASIL/GARDASIL 9 sales $5.7B (+44%).
- Molnupiravir contributed $952M in Q4; Animal Health sales $5.6B (+18%).
- FY2022 guidance: sales $56.1-$57.6B, GAAP EPS $5.76-$5.91, Non-GAAP EPS $7.12-$7.27.